ストックスクリーナーアプリを入手
202.88
2.43%
-5.05
アフターアワーズ：
202.95
0.07
+0.03%
前日終値:
$207.93
開ける：
$207.51
24時間の取引高:
795.04K
Relative Volume:
0.66
時価総額：
$29.95B
収益：
$9.60B
当期純損益:
$1.37B
株価収益率:
21.77
EPS:
9.3182
ネットキャッシュフロー:
$2.32B
1週間 パフォーマンス:
+0.34%
1か月 パフォーマンス:
-6.10%
6か月 パフォーマンス:
+12.78%
1年 パフォーマンス:
+58.50%
1日の値動き範囲:
$202.57
$208.05
1週間の範囲:
$199.40
$218.59
52週間の値動き範囲:
$124.56
$219.72
Biogen Inc Stock (BIIB) Company Profile
Compare BIIB vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
202.88 | 29.55B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
1,148.52 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.42 | 640.91B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
251.06 | 453.91B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
130.22 | 322.95B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
156.14 | 296.72B | 54.66B | 13.58B | 16.05B | 7.0171 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-22 | アップグレード | UBS | Neutral → Buy |
| 2026-04-20 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2026-04-14 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-10 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2025-11-06 | アップグレード | Stifel | Hold → Buy |
| 2025-09-25 | 開始されました | Jefferies | Buy |
| 2025-07-21 | 再開されました | Truist | Hold |
| 2025-04-28 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-04-04 | ダウングレード | Argus | Buy → Hold |
| 2025-02-11 | 開始されました | Bernstein | Mkt Perform |
| 2025-01-02 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | ダウングレード | Stifel | Buy → Hold |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-12-09 | ダウングレード | Jefferies | Buy → Hold |
| 2024-11-18 | ダウングレード | Needham | Buy → Hold |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-10-31 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-02-14 | 繰り返されました | Needham | Buy |
| 2024-02-14 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | ダウングレード | UBS | Buy → Neutral |
| 2023-12-20 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-12-07 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | 開始されました | HSBC Securities | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
| 2023-07-24 | 繰り返されました | UBS | Buy |
| 2023-05-01 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-04-17 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | アップグレード | Goldman | Neutral → Buy |
| 2022-10-13 | アップグレード | Stifel | Hold → Buy |
| 2022-10-07 | アップグレード | Argus | Hold → Buy |
| 2022-09-28 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | アップグレード | Mizuho | Neutral → Buy |
| 2022-09-28 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | ダウングレード | Stifel | Buy → Hold |
| 2022-03-03 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-04 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-04 | 繰り返されました | Cowen | Outperform |
| 2022-02-04 | 繰り返されました | Morgan Stanley | Overweight |
| 2022-02-04 | 繰り返されました | Needham | Buy |
| 2022-02-04 | 繰り返されました | Oppenheimer | Outperform |
| 2022-02-04 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | 繰り返されました | Robert W. Baird | Neutral |
| 2022-02-04 | 繰り返されました | Wedbush | Neutral |
| 2022-02-04 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-02-04 | 繰り返されました | Wolfe Research | Peer Perform |
| 2022-01-13 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-01-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | 再開されました | Raymond James | Mkt Perform |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-09-23 | 開始されました | Needham | Buy |
| 2021-06-18 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | 繰り返されました | Truist | Buy |
| 2021-06-11 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | アップグレード | UBS | Neutral → Buy |
| 2021-06-08 | アップグレード | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | 繰り返されました | Barclays | Equal Weight |
| 2021-06-08 | アップグレード | Citigroup | Sell → Neutral |
| 2021-06-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-08 | 繰り返されました | Jefferies | Buy |
| 2021-06-08 | 繰り返されました | Morgan Stanley | Overweight |
| 2021-06-08 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | 繰り返されました | Stifel | Buy |
| 2021-06-08 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-06-07 | アップグレード | Cowen | Market Perform → Outperform |
| 2021-06-07 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | ダウングレード | DZ Bank | Buy → Hold |
| 2021-01-29 | アップグレード | Stifel | Hold → Buy |
| 2020-11-10 | アップグレード | DZ Bank | Hold → Buy |
| 2020-11-09 | ダウングレード | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-11-09 | ダウングレード | Cowen | Outperform → Market Perform |
| 2020-11-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-11-04 | アップグレード | BofA Securities | Underperform → Neutral |
| 2020-11-04 | アップグレード | Jefferies | Hold → Buy |
| 2020-11-04 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-07-27 | アップグレード | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2020-06-22 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | ダウングレード | Citigroup | Neutral → Sell |
| 2020-04-23 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-01-27 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | ダウングレード | Robert W. Baird | Neutral → Underperform |
すべてを表示
Biogen Inc (BIIB) 最新ニュース
Biogen earnings on deck: Can Alzheimer’s drugs sustain momentum? By Investing.com - Investing.com Canada
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates? - Yahoo Finance
Biogen (BIIB) Reports Q2: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Barclays Adjusts Biogen Price Target to $200 From $185, Maintains Equalweight Rating - marketscreener.com
The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals - Yahoo! Finance Canada
Biogen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Biogen Q2 2026 Earnings Preview — July 29, Street Expects $2.10 EPS - AlphaStreet
BIIB|Biogen Inc|Price:200.140| - TradingKey
(BIIB) Volatility Zones as Tactical Triggers - Stock Traders Daily
Biogen Inc (BIIB) Institutional Confidence - TradingKey
Orbimed Advisors LLC Makes New $11.29 Million Investment in Biogen Inc. $BIIB - MarketBeat
Biogen stock trades steady as Alzheimer’s franchise and pipeline shape earnings outlook - Ad-hoc-news.de
Biogen Inc (BIIB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Biogen stock trades steady as Alzheimer’s data and revenue trends shape investor focus - AD HOC NEWS
Dimensional Fund Advisors LP Increases Stock Position in Biogen Inc. $BIIB - MarketBeat
Biogen Q2 Earnings: Can New Drugs Counter Falling MS Sales? - TradingView
Biogen’s Alzheimer’s data spur excitement, confusion about tau-targeting drugs - Endpoints News
Biogen Inc (BIIB) Valuation: PE, PB & Fair Value Analysis - TradingKey
First Trust Advisors LP Purchases 108,111 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen bets newly acquired Apellis can paper over Leqembi's disappointing sales into 2027 - Endpoints News
At-Home LEQEMBI Autoinjector And New Tau Data Might Change The Case For Investing In Biogen (BIIB) - simplywall.st
Biogen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Biogen, Pfizer vet joins Formation Bio as CSO - The Pharma Letter
Biogen CEO: Lessons from Biopharma on Leading Reinvention - WSJ
Biogen stock trades steady as revenue growth and Alzheimer’s portfolio shape outlook - Ad-hoc-news.de
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Former Biogen Executive to Lead Research at Formation Bio - Bloomberg
Biogen (BIIB) to Post Earnings on Wednesday - MarketBeat
Mediolanum International Funds Ltd Invests $1.14 Million in Biogen Inc. $BIIB - MarketBeat
SEB Asset Management AB Makes New Investment in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Stake Raised by Swiss National Bank - MarketBeat
Andra AP fonden Has $9.53 Million Stake in Biogen Inc. $BIIB - MarketBeat
Biogen And The Limitation Of The Tau Approach To Alzheimer's Disease - Seeking Alpha
Total liabilities & shareholders' equities of Biogen Inc. – BCS:BIIB1 - TradingView
Discontinued operations of Biogen Inc. – BCS:BIIB0 - TradingView
BIIB Maintained by B of A Securities -- Price Target Lowered to $215 - GuruFocus
BofA Securities Adjusts Biogen Price Target to $215 From $217 - marketscreener.com
Guggenheim Adjusts Price Target on Biogen to $280 From $260, Maintains Buy Rating - marketscreener.com
BofA cuts Biogen stock price target on higher expectations bar - Investing.com
BofA cuts Biogen stock price target on higher expectations bar By Investing.com - Investing.com Canada
KBC Group NV Raises Stock Position in Biogen Inc. $BIIB - MarketBeat
Biogen stock steadies as Alzheimer’s launch and pipeline guide long-term growth - Ad-hoc-news.de
Biogen (BIIB) Expands Its Alzheimer’s Pipeline, Is The 9% Undervaluation Still There? - simplywall.st
FDA 'Gets to Pick the Jury': Steve Uden on Biogen's Tau Gamble and a UK Political Reset - finance.biggo.com
Lobbying Update: $1,060,000 of BIOGEN lobbying was just disclosed - Quiver Quantitative
U.K. cabinet shuffle, Taiwan biotech and Biogen data — a BioCentury podcast - biocentury.com
Biogen Brings On Spur Therapeutics CEO As Legal Chief - Law360
Goldman Sachs Adjusts Price Target on Biogen to $271 From $250, Maintains Buy Rating - marketscreener.com
Biogen Inc. (BIIB) Stock Analysis: Exploring a 9.86% Potential Upside Amid Robust Therapeutic Portfolio - DirectorsTalk Interviews
Biogen Inc. $BIIB Shares Purchased by California Public Employees Retirement System - MarketBeat
Biogen Inc (BIIB) 財務データ
収益
当期純利益
現金流量
EPS
Biogen Inc (BIIB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Keeney Adam | Head of Corporate Development |
May 01 '26 |
Option Exercise |
0.00 |
939 |
0 |
6,820 |
| Godbout Sean | Chief Accounting Officer |
Apr 01 '26 |
Option Exercise |
0.00 |
181 |
0 |
1,396 |
| Murphy Nicole | Head of Pharm Ops and Tech |
Feb 12 '26 |
Buy |
195.03 |
3 |
585 |
19,611 |
| Viehbacher Christopher | President and CEO |
Feb 06 '26 |
Option Exercise |
0.00 |
24,461 |
0 |
36,548 |
| Singhal Priya | Head of Development |
Feb 06 '26 |
Option Exercise |
0.00 |
6,900 |
0 |
12,115 |
| Singhal Priya | Head of Development |
Feb 09 '26 |
Sale |
199.83 |
2,660 |
531,548 |
8,043 |
| Murphy Nicole | Head of Pharm Ops and Tech |
Feb 06 '26 |
Option Exercise |
0.00 |
8,725 |
0 |
21,016 |
| Kramer Robin | Chief Financial Officer |
Feb 06 '26 |
Option Exercise |
0.00 |
5,003 |
0 |
12,535 |
| Keeney Adam | Head of Corporate Development |
Feb 06 '26 |
Option Exercise |
0.00 |
5,080 |
0 |
6,875 |
| Izzar Rachid | Head of Global Product Strat. |
Feb 06 '26 |
Option Exercise |
0.00 |
6,889 |
0 |
11,786 |
0.48%
0.82%
大文字化:
|
ボリューム (24 時間):